LivaNova makes medical devices for heart and lung surgery and neuromodulation, including a system for treating sleep apnea. LIVN reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | Barclays | Initiated | Buy | |
| Sep 2 | Piper Sandler | Reiterated | Buy | |
| Aug 5 | Needham | Maintained | Buy | |
| Jul 15 | Mizuho | Maintained | Buy | |
| Jul 1 | Freedom Capital Markets | Initiated | Hold |
Whale Options Flow
90DNo whale options trades in LIVN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LIVN is in one of them and how their past LIVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LIVN in an article yet. Here's the latest on the wider market.
About LivaNova
LivaNova is a medical device company based in Gloucester, UK. Its Cardiopulmonary business sells perfusion systems and related consumables used in surgery involving the heart and lungs. Its Neuromodulation business offers devices, including a system in development for treating sleep apnea. The company sells its products in the United States, Europe and other regions around the world.
- Headquarters
- Gloucester